Profile
Mitchell Golbus was a Professor at The University of California, San Francisco from 1981 to 1994.
He was also the President & Chief Medical Officer at Diamics, Inc. Dr. Golbus holds a doctorate degree from the University of Illinois.
Former positions of Mitchell Golbus
| Companies | Position | End |
|---|---|---|
Diamics, Inc.
 Diamics, Inc. Medical SpecialtiesHealth Technology Diamics Inc. is a medical technology company located in the San Francisco Bay Area. As an innovator in women’s health, the company develops breakthrough cancer diagnostic systems. Diamics’ management team has an extensive track record of success in the medical device, diagnostics and biotechnology industries. The company’s mission is to constantly improve cancer screening diagnostics and provide solutions for unmet medical needs in women’s health. Diamics has two products in near term (6-12 months) development timelines. One product, the TouchPap™, focuses on improving the ubiquitous Pap test and is scheduled for launch in 2009. Following on the heels of this launch will be products aimed at the rapidly expanding molecular diagnostics market, specifically targeting HPV and cervical cancer. | President | 2013-10-14 |
| The University of California, San Francisco | Corporate Officer/Principal | 1993-12-31 |
Training of Mitchell Golbus
| University of Illinois | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Diamics, Inc.
Diamics, Inc. Medical SpecialtiesHealth Technology Diamics Inc. is a medical technology company located in the San Francisco Bay Area. As an innovator in women’s health, the company develops breakthrough cancer diagnostic systems. Diamics’ management team has an extensive track record of success in the medical device, diagnostics and biotechnology industries. The company’s mission is to constantly improve cancer screening diagnostics and provide solutions for unmet medical needs in women’s health. Diamics has two products in near term (6-12 months) development timelines. One product, the TouchPap™, focuses on improving the ubiquitous Pap test and is scheduled for launch in 2009. Following on the heels of this launch will be products aimed at the rapidly expanding molecular diagnostics market, specifically targeting HPV and cervical cancer. | Health Technology |
- Stock Market
- Insiders
- Mitchell Golbus
